In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFJ Pharmaceuticals Inc.

www.sfj-pharma.com

Latest From SFJ Pharmaceuticals Inc.

Japan Approvals Include World Firsts For Romosozumab, Spinal Injury Cell Therapy

The latest group of new product approvals in Japan includes the first marketing clearances worldwide for fracture-reducing osteoporosis antibody romosozumab and a stem cell-based therapy for spinal cord injury, as well as two new Daiichi drugs and Pfizer's lung cancer therapy dacomitinib. 

Japan Approvals

Abingworth Closes 12th Life Sciences Fund ABV VII At $315M

European biotechs are likely to be the big winner as transatlantic VC Abingworth closes its latest fund, Abingworth Ventures VII (ABV VII), at $315m, exceeding its $300m target.

Analysis Commercial

Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer

SFJ Pharmaceuticals has taken on the late-stage clinical development of Merck KGaA's previously stalled MAb abituzumab, sharing the financial risk and evaluating patients with left-sided colorectal cancer.

 

Clinical Trials Research & Development

Pfizer's Axitinib Disappoints As RCC Adjuvant Therapy

An interim analysis has recommended stopping the Phase III ATLAS study because axitinib was failing to show it extended disease-free survival when used as adjuvant therapy in earlier-stage renal cell carcinoma patients. However, combination studies of axitinib with immuno-oncology agents will continue.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • SFJ Pharmaceuticals Inc.
  • Senior Management
  • Robert DeBenedetto, Pres. & CEO
    Bruce A Bouchard, EVP, CFO
    Stewart Hallett, EVP, COO
    Rolf Linke, MD, EVP, CMO
    Geoff Owen, EVP, CBO
  • Contact Info
  • SFJ Pharmaceuticals Inc.
    Phone: (925) 223-6233
    5000 Hopyard Rd.
    Ste. 330
    Pleasanton, CA 94588
    USA
UsernamePublicRestriction

Register